Tolvaptan
- Generic Name
- Tolvaptan
- Brand Names
- Jinarc, Jynarque 45/15 Carton, Samsca, Tolvaptan Accord, Xeljanz
- Drug Type
- Small Molecule
- Chemical Formula
- C26H25ClN2O3
- CAS Number
- 150683-30-0
- Unique Ingredient Identifier
- 1E2497LPNY
- Background
Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
- Indication
Treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis.
- Associated Conditions
- Autosomal Dominant Polycystic Kidney Disease （ADPKD), Symptomatic euvolemic Hyponatremia, Symptomatic hypervolemic Hyponatremia
- Associated Therapies
- -
Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 105711
- Registration Number
- NCT04772248
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2021-02-15
- Target Recruit Count
- 414
- Registration Number
- NCT04750317
- Locations
- 🇷🇺
Sechenov First Moscow State Medical University (Sechenov University) - University Clinical Hospital, Moscow, Russian Federation
Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7807
- Registration Number
- NCT04721821
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT04624230
- Locations
- 🇺🇸
Center for Advanced Pediatrics, Atlanta, Georgia, United States
🇺🇸Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta, Georgia, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 270
- Registration Number
- NCT04610476
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
A Study of JNJ-64251330 in Healthy Participants
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT04552197
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 29464
- Registration Number
- NCT04529876
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 32
- Registration Number
- NCT04505410
- Locations
- 🇺🇸
The University of Miami, Miami, Florida, United States
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2024-07-30
- Target Recruit Count
- 76
- Registration Number
- NCT04496960
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Dr. Frank Behrens
- Target Recruit Count
- 92
- Registration Number
- NCT04485325
- Locations
- 🇩🇪
CIRI - Centrum für innovative Diagnostik & Therapie, Rheumatologie/ Immunologie GmbH, Frankfurt, Germany
🇩🇪Praxis Prof. Dr. Kellner, München, Germany
🇩🇪Rheumatologische Schwerpunktpraxis im Ärztehaus am Walter-Schreiber-Platz, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.